| http://www.w3.org/ns/prov#value | - But Dovey says it doesn???t preclude the U.S. startups from negotiating exclusive licensing agreements with Big Pharma partners in Europe, the United States, and other markets, nor does it preclude Rusnano from investing in other U.S. life sciences startups.
|
